| 1.42 0.05 (3.65%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.03 | 1-year : | 2.41 |
| Resists | First : | 1.74 | Second : | 2.06 |
| Pivot price | 1.38  |
|||
| Supports | First : | 1.22 | Second : | 1.01 |
| MAs | MA(5) : | 1.33 |
MA(20) : | 1.48 |
| MA(100) : | 1.39 |
MA(250) : | 1.39 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 15.1 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 2.23 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMEA ] has closed below upper band by 43.8%. Bollinger Bands are 37.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.46 |
| Low: | 1.37 - 1.37 | 1.37 - 1.38 |
| Close: | 1.41 - 1.42 | 1.42 - 1.43 |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Sun, 27 Sep 2026
BMEA Stock Slides As Biomea Fusion Pulls Equity Offering - Timothy Sykes
Sat, 26 Sep 2026
BMEA Stock Slides As Biomea Fusion Pulls Equity Offering - Timothy Sykes
Wed, 23 Sep 2026
Biomea Fusion Announces Termination of Proposed Public Offering of Securities - GlobeNewswire
Wed, 23 Sep 2026
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - TradingView
Wed, 23 Sep 2026
Biomea Fusion Announces Termination of Proposed Public Offering of Securities - Investing News Network
Tue, 22 Sep 2026
No size or terms are set for Biomea Fusion's share offering. Its underwriter may buy up to 15% more. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 40 (%) |
| Shares Short | 9,820 (K) |
| Shares Short P.Month | 10,450 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.5 % |
| Return on Equity (ttm) | -164.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -7.89 |
| PEG Ratio | 0 |
| Price to Book value | 8.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|